Valvoline's growth strategy remains strong despite macroeconomic challenges. VVV stock has continued to expand the franchise ...

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.

NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Seaport Research Partners (SRP), a rapidly expanding and innovative ...